Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Language: Английский

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions DOI

Yumna Khan,

Sana Rizvi, Ali Raza

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Language: Английский

Citations

1
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target DOI
Giannis Mountzios, Stephanie P.L. Saw, Lizza E.L. Hendriks

et al.

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 134, P. 102902 - 102902

Published: Feb. 16, 2025

Language: Английский

Citations

0
Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy DOI

A. O. Makarova,

E. V. Svirshchevskaya, Mikhail Titov

et al.

Russian Journal of Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: 51(2), P. 556 - 573

Published: April 1, 2025

Language: Английский

Citations

0
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities DOI
Shiwei Song, Yahui Liu, Jiaqi Liu

et al.

Bioconjugate Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

The heterobifunctional proteolysis targeting chimeras (PROTACs) are a class of emerging therapeutic modalities that enable selective degradation target proteins in cells. As antibody payloads, they offer several advantages compared to conventional chemical toxins, such as catalytic nature, potent and long-lasting activity, precise selectivity avoid systemic toxicity. However, the relatively large size high hydrophobicity these chimeric payloads may result challenging stability antibodies, which complicates vivo performance. In this work, we use highly hydrophobic GNE-987 model PROTAC evaluate THIOMAB approach for mitigating conjugate's while maintaining potency. We describe an silico method select less site employ stable tetrapeptide-aminomethoxy linker conjugate payloads. resulting degrader-antibody (J591 DAC) displays antigen-dependent BRD4 cytotoxic activity PSMA-positive cancer Finally, DAC, bearing two PROTACs, also exhibits long blood retention strong antitumor efficacy mouse models, likely owing homogeneous conjugation from approach. This work provides example design construction conjugates with

Language: Английский

Citations

0
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Language: Английский

Citations

0